Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/20156
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Butkeviciute, E | - |
dc.contributor.author | Jones, CE | - |
dc.contributor.author | Smith, SG | - |
dc.date.accessioned | 2020-02-03T12:59:22Z | - |
dc.date.available | 2018-08 | - |
dc.date.available | 2020-02-03T12:59:22Z | - |
dc.date.issued | 2018-08-17 | - |
dc.identifier.citation | Future Microbiology, 2018, 13 (10), pp. 1193 - 1208 | en_US |
dc.identifier.issn | 1746-0913 | - |
dc.identifier.issn | 1746-0921 | - |
dc.identifier.uri | https://bura.brunel.ac.uk/handle/2438/20156 | - |
dc.description.abstract | The current antituberculosis vaccine, BCG, was derived in the 1920s, yet the mechanisms of BCG-induced protective immunity and the variability of protective efficacy among populations are still not fully understood. BCG challenges the concept of vaccine specificity, as there is evidence that BCG may protect immunized infants from pathogens other than Mycobacterium tuberculosis – resulting in heterologous or nonspecific protection. This review summarizes the up-to-date evidence for this phenomenon, potential immunological mechanisms and implications for improved childhood vaccine design. BCG induces functional changes in infant innate and adaptive immune compartments, encouraging their collaboration in the first year of life. Understanding biological mechanisms beyond heterologous BCG effects is crucial to improve infant protection from infectious diseases. | en_US |
dc.description.sponsorship | MRC; IMmunising PRegnant women and INfants neTwork (IMPRINT); GCRF Networks in Vaccines Research and Development; BBSRC; the National Vaccine Program Office (NVPO); Bill & Melinda Gates Foundation; Novavax, GSK; Janssen; European Commission; Horizon2020 TBVAC2020 (Grant No. H2020 PHC-643381); GCRF Networks in Vaccines Research and Development VALIDATE Network which was co-funded by the MRC and BBSRC (Grant No. MR/R005850/1). | en_US |
dc.format.extent | 1193 - 1208 | - |
dc.language | en | - |
dc.language.iso | en | en_US |
dc.publisher | Future Medicine Ltd | en_US |
dc.subject | BCG | en_US |
dc.subject | childhood immunization | en_US |
dc.subject | heterologous vaccine effects | en_US |
dc.subject | humoral responses | en_US |
dc.subject | infant immunity | en_US |
dc.title | Heterologous effects of infant BCG vaccination: potential mechanisms of immunity | en_US |
dc.type | Article | en_US |
dc.identifier.doi | https://doi.org/10.2217/fmb-2018-0026 | - |
dc.relation.isPartOf | Future Microbiology | - |
pubs.issue | 10 | - |
pubs.publication-status | Published | - |
pubs.volume | 13 | - |
dc.identifier.eissn | 1746-0921 | - |
Appears in Collections: | Dept of Life Sciences Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
FullText.pdf | 2.98 MB | Adobe PDF | View/Open |
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.